NCT07382076 (ACT) is a clinical trial of Blood draw in Activated Clotting Time, sponsored by Abbott Point of Care.

Who is sponsoring NCT07382076?

NCT07382076 is sponsored by Abbott Point of Care.

What drugs are being tested in NCT07382076?

Interventions in NCT07382076: Blood draw.

What condition does NCT07382076 study?

NCT07382076 studies Activated Clotting Time.

Is NCT07382076 still recruiting?

NCT07382076 is currently active, enrolled. Last updated 2 February 2026.

Last reviewed 2026-02-02 · How we verify

NCT07382076: ACT

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Clinical Evaluation of the i-STAT ACTpro Cartridge in an Adult Population

Active, enrolled Last updated 2 February 2026

What this trial tests

trial testing Blood draw in Activated Clotting Time in 500 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

15 December 2023

Primary endpoint
30 March 2026

30 March 2026

Quick facts

Lead sponsor	Abbott Point of Care
Status	Active, enrolled
Study type	OBSERVATIONAL
Enrollment	500
Start date	15 December 2023
Primary completion	30 March 2026
Estimated completion	30 March 2026
Sites	11 locations across United States

Drugs / interventions tested

Blood draw — full drug profile →

Conditions studied

Activated Clotting Time — all drugs for Activated Clotting Time →

Sponsor

Abbott Point of Care

Who can join

18 and older, any sex, with Activated Clotting Time. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Measuring Activated Clotting Time (ACT) using the i-STAT ACTpro cartridge on the i-STAT 1 analyzer compared to a comparator device.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Blood draw

Trials testing the same drug.

NCT07518784 — Accurate Point of Care Liver Disease Diagnostics (Phase 2) · recruiting
NCT07252622 — Progesterone Levels and Frozen Embryo Transfer Outcomes · not yet recruiting
NCT06011824 — A Study of Effect of Megakaryocytes and Platelets in Breast Cancer · completed
NCT05912400 — Evaluating Mitochondrial Dysfunction in Patients With Neurofibromatosis Type 1 · completed
NCT05735730 — Can the Risk for AMD be Modulated? · NA · active not recruiting

Other recruiting trials for Activated Clotting Time

Currently open trials in the same condition.

NCT06109155 — The Effect of ACT and Tranexamic Acid on Bleeding in Cardiac Surgery · Phase 4 · recruiting

Other Abbott Point of Care trials

Trials by the same sponsor.

NCT06295835 — Method Comparison Study for Measuring Potassium (K) and Ionized Calcium (iCa) in Blood · NA · completed
NCT06291493 — Precision Study Measuring Potassium (K) in Capillary Specimens · NA · completed
NCT05629572 — Abbott i-STAT High Sensitivity Troponin I Study · completed
NCT04171960 — Clinical Evaluation of the i-STAT TBI Test · completed
NCT02897154 — Clinical Evaluation of i-STAT Analyzer Glucose, Hematocrit and Sodium for Capillary Samples · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07382076 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Abbott Point of Care
Last refreshed: 2 February 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07382076.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing